GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » PB Ratio
中文

Enanta Pharmaceuticals (Enanta Pharmaceuticals) PB Ratio

: 1.44 (As of Today)
View and export this data going back to 2013. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), Enanta Pharmaceuticals's share price is $13.10. Enanta Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was $9.07. Hence, Enanta Pharmaceuticals's PB Ratio of today is 1.44.

The historical rank and industry rank for Enanta Pharmaceuticals's PB Ratio or its related term are showing as below:

ENTA' s PB Ratio Range Over the Past 10 Years
Min: 0.8   Med: 2.93   Max: 8.38
Current: 1.44

During the past 13 years, Enanta Pharmaceuticals's highest PB Ratio was 8.38. The lowest was 0.80. And the median was 2.93.

ENTA's PB Ratio is ranked better than
69.01% of 1310 companies
in the Biotechnology industry
Industry Median: 2.38 vs ENTA: 1.44

During the past 12 months, Enanta Pharmaceuticals's average Book Value Per Share Growth Rate was -37.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -23.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -12.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 7.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Enanta Pharmaceuticals was 32.00% per year. The lowest was -23.20% per year. And the median was 15.05% per year.

Back to Basics: PB Ratio


Enanta Pharmaceuticals PB Ratio Historical Data

The historical data trend for Enanta Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enanta Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 2.02 2.88 3.36 1.09

Enanta Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 3.16 1.89 1.09 1.04

Competitive Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's PB Ratio falls into.



Enanta Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Enanta Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=13.10/9.07
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Enanta Pharmaceuticals  (NAS:ENTA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Enanta Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals (Enanta Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
500 Arsenal Street, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Terry Vance director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Scott T. Rottinghaus officer: Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Brendan Luu officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Tara Lynn Kieffer officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Yat Sun Or officer: Chief Scientific Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Jay R. Luly director, officer: President and CEO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathaniel S. Gardiner director C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Paul J Mellett officer: Treasurer and CFO C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Nathalie Adda officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Mark G Foletta director AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901

Enanta Pharmaceuticals (Enanta Pharmaceuticals) Headlines

From GuruFocus

Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

By Business Wire Business Wire 05-09-2023